Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma

Bone Marrow Transplantation

Volumn 30, Issue 11, 2002, Pages 769-775

  Thieblemont, C ^a   Dumontet, C ^a   Saad, H ^a   Roch, N ^a   Bouafia, F ^a   Arnaud, P ^a   Hequet, O ^a   Espinouse, D ^a   Salles, G ^a   Roy, P ^a   Eljaafari Corbin, A ^b   du Manoir Baumgarten, C ^c   Coiffer, B ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c NONE

Author keywords

Amifostine; Cytoprotection; High dose melphalan; Mucositis; Myeloma

Indexed keywords

AMIFOSTINE; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CD34 ANTIGEN; CLORAZEPATE DIPOTASSIUM; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; OPIATE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ANOREXIA; ARTICLE; AUTOTRANSPLANTATION; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOCALCEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; MALE; MOUTH DISEASE; MOUTH MUCOSA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUROMUSCULAR DISEASE; PARESTHESIA; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; VOMITING;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRAFT SURVIVAL; HUMANS; KINETICS; MALE; MELPHALAN; MIDDLE AGED; MOUTH MUCOSA; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STOMATITIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0036901903     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703757     Document Type: Article

References (33)

1. Alexanian R, Dimopoulos M. Management of multiple myeloma. Semin Hematol 1995; 32: 20-30.
2. Camba L, Durie B. Multiple myeloma. New treatment options. Drugs 1992; 44: 170-181.
3. Gregory W, Richards M, Malpas J. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334-342.
4. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
5. Selby P, McElwain T, Nandi A et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55-62.
6. Attal M, Harousseau J, Stoppa A et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New Engl J Med 1996; 335: 91-97.
7. Cunningham D, Paz-Ares L, Gore M et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol 1994; 12: 764-768.
8. Samuels B, Bitran J. High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786-1799.
9. Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 2001; 27 (Suppl. 2): S3-S11.
10. Hensley M, Schuchter L, Lindley C et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17: 3333-3355.
11. Davidson D, Grenan M, Sweeney T. Biological characteristics of some improved radioprotectors. In: Brady L (ed.). Radiation Sensitizers. Masson: New York, 1980, pp 309-320.
12. Glover D, Glick J, Weiler C et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986; 4: 584-588.
13. Turrisi A, Glover D, Hurwitz S et al. Final report of the phase I trial of single-dose WR-2721 (S-2-(3-aminopropylamino)ethylphosphorothioic acid). Cancer Treat Rep 1986; 70: 1389-1393.
14. Kemp G, Rose P, Lurain J et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-2112.
15. Yuhas J, Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 1980; 64: 57-64.
16. Treskes M, Boven E, Holwerda U et al. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. Cancer Res 1992; 52: 2257-2260.
17. Mollman J, Glover D, Hogan W, Furman R. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988; 61: 2192-2195.
18. Schuchter LM, Glick JH. The current status of WR2721 (amifostine) a chemotherapy and radiation therapy protector in biologic therapy of cancer updates. In: De Vita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practices of Oncology. JB Lippincott: Philadelphia, 1993, pp 1-9.
19. Green D, Bensely D, Schein P. Preclinical evaluation of WR-151327: an orally active chemotherapy protector. Cancer Res 1994; 54: 738-741.
20. Glover D, Riley L, Carmichael K et al. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). New Engl J Med 1983; 309: 1137-1141.
21. List A, Heaton R, Glinsmann-Gibson B, Capizzi R. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 1996; 23 (Suppl. 8): 58-63.
22. Schuchter L. Guidelines for the administration of amifostine. Semin Oncol 1996; 23 (Suppl. 8): 40-43.
23. Bukowski R. Amifostine (ethyol): dosing, administration and patient management guidelines. Eur J Cancer 1996; 32A (Suppl. 4): S46-S49.
24. World Health Organization. Handbook for Reporting Results of Cancer Treatment. World Health Organisation: Geneva, 1979.
25. Capelli D, Santini G, De Souza C et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study. Br J Haematol 2000; 110: 300-307.
26. Cronin S, Uberti J, Ayash L et al. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 26: 1247-1249.
27. Hartmann J, von Vangerow A, Fels L et al. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 2001; 84: 313-320.
28. Campilho F, Campos A, Vas C et al. Amifostine (AMI) before high-dose mephalan (HDMel) and autologous hematopoietic stem cell transplantation for patients with multiple myeloma (MM) - a case control analysis. Blood 2001; 98: 839.
29. van der Vijgh W, Korst A. Amifostine (ethyol): pharmacokinetic and pharmacodynamic effects in vivo. Eur J Cancer 1996; 32A (Suppl. 4): S26-S30.
30. Shpall E, Stemmer S, Hami L et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994; 83: 3132-3137.
31. Pico J, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998; 3: 446-451.
32. Yuhas J. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1980; 40: 1519-1524.
33. Wasserman T, Phillips T, Ross G, Kane L. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721. Cancer Clin Trials 1981; 4: 3-6.